Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), announced on October 17, 2022, a Medical Device Correction for all Omnipod DASH® Personal Diabetes Managers ...

The FDA posted a notice saying the recall of Insulet's Omnipod DASH Insulin Management System Personal Diabetes Manager is a Class I, the most serious recall indicating the devices could cause serious ...

Insulet Corporation PODD continues to gain on solid prospects in the diabetes market. The company is progressing well with respect to its four-pillar strategy. The stock carries a Zacks Rank #2 (Buy).

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

Narrow-moat Insulet saw another strong quarter that wrapped up an entire year of impressive growth on the top and bottom lines. Though we haven’t shifted our assumptions, we might modestly raise our ...